According to reports, the investigational TROP2-targeting antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT), developed through a collaboration between Kelun-Biotech (06990) and Merck (MRK.US), has achieved the primary overall survival (OS) endpoint in the pivotal Phase III TroFuse-015 study.
sac-TMT is the first TROP2 ADC globally to demonstrate improved OS compared with physician's choice of treatment (TPC) in a global Phase III study among patients with advanced gastroesophageal adenocarcinoma who had previously received two or more lines of systemic therapy. The TroFuse-015 study evaluated sac-TMT for the treatment of locally advanced unresectable or metastatic gastroesophageal adenocarcinoma, with the comparator TPC regimen including trifluridine/tipiracil, irinotecan, paclitaxel, or docetaxel. This marks the first time a TROP2 ADC has demonstrated an OS benefit in a global Phase III trial for this patient population, where there remains a significant unmet need. The data will be presented at an upcoming medical conference and shared with regulatory authorities.
The final analysis showed that for these patients who had previously received two or more lines of systemic therapy, sac-TMT achieved a statistically significant and clinically meaningful improvement in OS compared with TPC. Results were generally consistent across subgroups regardless of TROP2 expression status. sac-TMT did not meet the secondary endpoint of progression-free survival (PFS) as assessed by blinded independent central review (BICR). Additionally, the secondary endpoint of objective response rate (ORR) showed a numerical improvement favoring sac-TMT, but was not formally tested per the prespecified analysis plan. The safety profile was consistent with previously reported sac-TMT studies, with no new safety signals observed.
Dr. Marjorie Green, Senior Vice President and Head of Global Clinical Development, Oncology, at Merck Research Laboratories, said: "sac-TMT is the first TROP2 ADC to improve OS compared with TPC in a global Phase III study of advanced gastroesophageal adenocarcinoma, demonstrating its potential in this particularly challenging disease setting. These patients have a tremendous unmet need for therapies that can improve survival. We look forward to discussing these data with regulatory authorities on behalf of patients who may benefit and sharing them with the scientific community."
TroFuse-015 is also the second positive Phase III study from Merck's sac-TMT TroFuse clinical development program. The program currently includes 18 ongoing global Phase III trials, covering a broader range of diseases and treatment settings than any TROP2-targeting ADC to date. The program is evaluating sac-TMT in multiple tumor types including endometrial cancer, bladder cancer, breast cancer, cervical cancer, gastric cancer, non-small cell lung cancer, and ovarian cancer, spanning from early to late-stage disease, both as monotherapy and in combination with immunotherapy. Within the program, 14 of the 18 Phase III studies are exploring first-in-class opportunities to address unmet medical needs, including TroFuse-015.
Public information shows that Kelun-Biotech, as the innovative drug platform within the Kelun system, has accumulated over a decade of ADC research and development experience and is the first Chinese company to establish ADC collaborations with top ten multinational pharmaceutical companies. sac-TMT (sacituzumab tirumotecan, brand name Jiataile®) is the company's core asset and the world's first TROP2 ADC approved for a lung cancer indication. It has currently received four approvals in China, covering triple-negative breast cancer, EGFR-mutant non-small cell lung cancer, and HR+/HER2- breast cancer, with the first two included in medical insurance. The drug has also received six breakthrough therapy designations from the National Medical Products Administration.
The overseas rights to sac-TMT originate from a licensing agreement in May 2022. At that time, Kelun-Biotech exclusively granted Merck the rights to develop, use, manufacture, and commercialize the drug (SKB264, Merck code MK-2870) outside Greater China, and received non-refundable payments of $17 million and $30 million upon the agreement's effectiveness and after the signing of an amendment, respectively, with cumulative milestone payments not exceeding $1.363 billion, plus tiered royalties on net sales. Since then, the two parties have successively reached licensing agreements for SKB315 and seven preclinical ADC assets, with total upfront and milestone payments from transactions since May 2022 potentially exceeding $11.8 billion. Currently, all overseas clinical studies of sac-TMT are sponsored and led by Merck.
Comments